abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

IL4R
Back
Total number of drugs
96
Phase II and later clinical stages
13.5%
Involving companies
112
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
PM-1268PM-1268Bispecific antibodyNeoplasmsIL-31 inhibitors IL-4Rα inhibitorsBiotheus, Inc.-Discontinued (in Preclinical)Discontinued (in Preclinical)--------PM-1268--
detail  >
CN117924499CN117924499Monoclonal antibodyImmune System Diseases Infectious Diseases Eye Diseases Hemic and Lymphatic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases-KANGLITAI BIOMEDICAL (QINGDAO) CO., LTDKANGLITAI BIOMEDICAL (QINGDAO) CO., LTDDiscovery---------CN117924499--
detail  >
WO2024242455WO2024242455NanobodyOther Diseases-Industry Academic Cooperation Foundation of Hongik UniversityYonsei Industry-Academic Cooperation FoundationIndustry Academic Cooperation Foundation of Hongik UniversityYonsei Industry-Academic Cooperation FoundationDiscovery---------WO2024242455--
detail  >
CN116887858CN116887858Monoclonal antibodyImmune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases-Regeneron Pharmaceuticals, Inc.Sanofi Biotechnology SASSanofi Biotechnology SASRegeneron Pharmaceuticals, Inc.Discovery---------CN116887858--
detail  >
IL-4Ra (Generian)IL-4Ra (Generian)Small molecule drug-IL-4Rα modulatorsGenerian Pharmaceuticals, Inc.Generian Pharmaceuticals, Inc.Discovery---------IL-4Ra (Generian)--
detail  >
BET207-01BET207-01NanobodyImmune System Diseases Infectious Diseases Congenital Disorders Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal DiseasesIL-4Rα inhibitorsBonentai (Shandong) Biomedical Technology Group Co., Ltd.-Discontinued (in Preclinical)Discontinued (in Preclinical)--------BET207-01--
detail  >
PM-1017PM-1017Bispecific antibodyNeoplasmsIL-4Rα inhibitors IL-5 inhibitorsBiotheus, Inc.-Discontinued (in Preclinical)Discontinued (in Preclinical)--------PM-1017--
detail  >
IL-4R(Amgen, Inc.)IL-4R(Amgen, Inc.)Recombinant proteinImmune System Diseases Respiratory DiseasesIL-4Rα modulatorsAmgen, Inc.-Discontinued (in Phase 2)---------IL-4R(Amgen, Inc.)--
detail  >
BizaxofuspBizaxofuspAntibody toxin conjugateNeoplasms Nervous System Diseases Other Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital DiseasesIL-4Rα modulatorsNeurocrine Biosciences, Inc.-Discontinued (in Phase 2)----Fast Track(United States) Orphan Drug(European Union) Orphan Drug(United States)----Bizaxofusp--
detail  >
IL4R/IL25-BsAb (Novarock)IL4R/IL25-BsAb (Novarock)Bispecific antibodyImmune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal DiseasesIL-25 inhibitors IL-4Rα inhibitorsNovarock Biotherapeutics Ltd.Novarock Biotherapeutics Ltd.Discovery---------IL4R/IL25-BsAb (Novarock)--
detail  >
Total 96 data
1
2
3
4
5
6
...
9
10